Short-Term Rationing of Combination Antiretroviral Therapy: Impact on Morbidity, Mortality, and Loss to Follow-Up in a Large HIV Treatment Program in Western Kenya

Table 3

Cox proportional (unadjusted and adjusted) hazard ratios and 95% confidence intervals for morbidity, loss to follow-up, and mortality.

Morbidity

Loss to follow-up

Mortality

Unadjusted

Adjusted^b

Unadjusted

Adjusted^b

Unadjusted

Adjusted^b

Covariate

HR; (95% CI)

P value

HR; (95% CI)

P value

HR; (95% CI)

P value

HR; (95% CI)

P value

HR; (95% CI)

P value

HR; (95% CI)

P value

Enrolled during cap period

0.93; (0.83, 1.03)

0.162

0.92; (0.82, 1.03)

0.152

1.19; (1.11, 1.27)

<0.001

1.12; (1.04, 1.22)

0.004

1.31; (1.16, 1.48)

<0.001

1.21; (1.06, 1.39)

0.006

Use of Cotrimoxazole or Dapsone^a

0.66; (0.58, 0.76)

<0.001

0.67; (0.55, 0.80)

<0.001

0.39; (0.36, 0.42)

<0.001

0.58; (0.52, 0.65)

<0.001

0.49; (0.42, 0.56)

<0.001

0.46; (0.37, 0.57)

<0.001

TB treatment^a

0.82; (0.72, 0.93)

0.003

0.68; (0.59, 0.78)

<0.001

1.04; (0.97, 1.12)

0.299

0.99; (0.90, 1.09)

0.850

1.11 (0.97, 1.27)

0.136

0.84; (0.72, 0.99)

0.033

Male gender

0.98 (0.88, 1.09)

0.718

0.95; (0.85, 1.07)

0.418

1.05; (0.98, 1.12)

0.187

1.01; (0.93, 1.10)

0.760

1.48 (1.31, 1.67)

<0.001

1.36; (1.19, 1.57)

<0.001

Age (per year increase)^a

1.00; (0.99, 1.00)

0.333

1.00; (0.99, 1.01)

0.772

0.99 (0.98, 0.99)

<0.001

0.99; (0.98, 0.99)

<0.001

1.00; (1.00, 1.01)

0.388

1.00; (1.00, 1.01)

0.484

CD4 (per cell increase)^a

0.999; (0.999, 1.000)

0.006

0.998; (0.998, 0.999)

<0.001

0.999; (0.999, 0.999)

<0.001

0.999; (0.999, 0.999)

<0.001

0.995; (0.994, 0.996)

<0.001

0.995; (0.994, 0.996)

<0.001

WHO Stage I^a

1.00

1.00

1.00

1.00

1.00

1.00

WHO Stage II^a

1.24; (1.01, 1.51)

0.038

1.23; (1.01, 1.51)

0.044

0.95; (0.83, 1.09)

0.454

0.96; (0.83, 1.10)

0.543

1.19 (0.87, 1.63)

0.279

1.10; (0.80, 1.50)

0.572

WHO Stage III^a

1.49; (1.26, 1.78)

<0.001

1.64; (1.36, 1.96)

<0.001

1.32; (1.18, 1.49)

<0.001

1.24; (1.10, 1.40)

<0.001

2.62; (2.02, 3.40)

<0.001

2.44; (1.87, 3.19)

<0.001

WHO Stage IV^a

2.10; (1.68, 2.62)

<0.001

2.55; (2.01, 3.24)

<0.001

2.08; (1.80, 2.40)

<0.001

1.98; (1.70, 2.31)

<0.001

4.51; (3.37, 6.04)

<0.001

4.41; (3.24, 5.99)

<0.001

Urban Clinic^a

0.99; (0.89, 1.10)

0.857

0.99; (0.88, 1.11)

0.856

1.05; (0.99, 1.12)

0.128

1.02; (0.94, 1.10)

0.651

0.76; (0.68, 0.87)

<0.001

0.80; (0.70, 0.92)

0.002

Travel time < 30 min

1.00

1.00

1.00

1.00

1.00

1.00

Travel time 30–60 min

0.93; (0.80, 1.07)

0.305

0.95; (0.81, 1.10)

0.491

1.13; (1.03, 1.24)

0.009

1.14; (1.03, 1.27)

0.014

1.36; (1.14, 1.62)

<0.001

1.18; (0.97, 1.43)

0.098

Travel time 1-2 hr

1.04; (0.90, 1.21)

0.598

1.01; (0.86, 1.18)

0.908

1.07; (0.97, 1.17)

0.204

1.07; (0.96, 1.20)

0.231

1.30; (1.08, 1.56)

0.005

1.09; (0.89, 1.34)

0.390

Travel time > 2 hr

0.98; (0.83, 1.17)

0.846

0.93; (0.78, 1.12)

0.464

1.34; (1.20, 1.48)

<0.001

1.40; (1.24, 1.58)

<0.001

1.38; (1.12, 1.68)

0.002

1.16; (0.93, 1.45)

0.192

^aAt enrollment.
^bAdjusted for all covariates.